Anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy

A slow-release embolization and interventional therapy technology, applied in the fields of application, medical science, surgery, etc., can solve the problems of tumor recurrence and metastasis, affect the expected therapeutic effect of TACE, and cannot completely kill tumor cells, so as to inhibit neogenesis and avoid recurrence And the effect of transfer and convenient operation

Inactive Publication Date: 2021-07-16
太阳雨林(厦门)生物医药有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

TACE often cannot completely kill tumor cells, and postoperative tumor local ischemia and hypoxia activate specific angiogenesis factors, leading to the formation of new blood vessels, and the original hepatic blood vessels and new blood vessels form new collateral circulation, leading to tumor The recurrence and metastasis of patients affected the expected therapeutic effect of TACE

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy
  • Anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy
  • Anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The anti-tumor vascular drug slow-release embolic microspheres for interventional therapy of malignant tumors has a particle size of 10-1000 μm. It is loaded with anti-tumor vascular drugs for anti-tumor blood vessels, anti-tumor angiogenesis and anti-tumor angiogenesis. The anti-tumor vascular drugs are antibody drugs or small molecular compound drugs, which can resist or inhibit the original blood vessels of tumor tissues and can resist or inhibit the angiogenesis of tumor tissue, thereby inhibiting the formation of collateral circulation of tumor tissue and inhibiting the growth, metastasis and recurrence of tumor, among which

[0055] The above materials are chitin, chitosan or its derivatives, sodium alginate, gelatin, collagen, hyaluronic acid, polypeptide, silk fibroin, starch or its derivatives, polycaprolactone, polylactic acid, polyglycolic acid, Polylactic acid-polyglycolic acid copolymer, polylactic acid polycaprolactone, polylactic acid polycaprolactone cop...

Embodiment 2

[0078] The preparation of embodiment 2 sorafenib tosylate chitosan sustained-release embolism microspheres

[0079] (1) Preparation of microspheres

[0080]Dissolve an appropriate amount of bile salt in water, weigh sorafenib tosylate and evenly disperse in the bile salt solution to prepare a drug solution. A proper amount of chitosan was dissolved in 2% acetic acid solution to make 2% chitosan solution. Adding the drug solution into the chitosan solution, adding sodium tripolyphosphate as a cross-linking agent, and mixing evenly to obtain a microsphere preparation solution. Prepared by spray drying method, the equipment used is BUCHI Mini Spray Dryer B-290, the inlet temperature is 130°C, the outlet temperature is 75°C, the flow rate of the preparation solution is 6mL / min, the air pressure is 450kPa, and the air flow rate is 0.7m 3 / min, finally got as figure 1 Sorafenib tosylate chitosan sustained release embolic microspheres shown.

[0081] (2) Encapsulation efficiency...

Embodiment 3

[0093] Example 3 Preparation of Apatinib Mesylate Gelatin Sustained Release Embolization Microspheres

[0094] (1) Preparation of microspheres

[0095] Apatinib mesylate is dissolved in dilute acetic acid to prepare a drug solution. The prepared gelatin solution with a concentration of 10% is completely dissolved on a water bath at 50-60° C., and then the drug solution is added and mixed evenly to prepare a water phase. Add an appropriate amount of Span-80 to liquid paraffin to form the oil phase, place it in a three-neck flask in a constant temperature water bath at 50°C, and slowly add the water phase to the oil phase drop by drop under the condition of a stirring speed of 200-1000r·min-1 Emulsify in medium, the water-oil ratio is 1:4-1:8. After emulsification to form a stable W / O emulsion, quickly cool down to below 5°C, add formaldehyde or 50% glutaraldehyde to solidify for 1-2 hours, centrifuge the obtained product at 3000r / min, wash 3 times with isopropanol and acetone...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses an anti-tumor vascular drug sustained-release embolization microsphere for malignant tumor interventional therapy, which is made of a degradable or non-degradable material and is internally loaded with an anti-tumor vascular drug for resisting tumor vessels, tumor angiogenesis and tumor angiogenesis, and the drug comprises an antibody or small molecule compound drug. The growth of original blood vessels of tumor tissues and the angiogenesis of the tumor tissues can be resisted or inhibited, so that the formation of collateral circulation of the tumor tissues is inhibited, and the growth, metastasis and relapse of tumors are inhibited. According to the present invention, the tumor blood vessel is inhibited while the tumor tissue blood supply is embolized and blocked, the tumor angiogenesis and the tumor collateral circulation formation are inhibited, and the tumor recurrence and the tumor metastasis are effectively avoided. The anti-tumor vascular drug is slowly released in a tumor area, the high drug concentration can be kept at the tumor part for a long time, the drug concentration in systemic circulation is not too high, the drug utilization rate is increased, and the side effects of the drug are relatively reduced.

Description

technical field [0001] The invention belongs to the technical field of interventional medicine, and in particular relates to a slow-release embolic microsphere of an anti-tumor blood vessel drug for interventional treatment of malignant tumors. Background technique [0002] Transarterial chemoembolization (Transarterial chemoembolization, TACE) blocks the blood supply of tumor tissue and slowly releases local high-concentration chemotherapy drugs, which eventually leads to ischemia, hypoxia and necrosis of tumor tissue. One of the main methods for liver cancer, widely recognized for its efficacy and safety. TACE often cannot completely kill tumor cells, and postoperative tumor local ischemia and hypoxia activate specific angiogenesis factors, leading to the formation of new blood vessels, and the original hepatic blood vessels and new blood vessels form new collateral circulation, leading to tumor recurrence and metastasis, affecting the expected therapeutic effect of TACE....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L24/10A61L24/08A61L24/06A61L24/04A61L24/00
CPCA61L24/08A61L24/104A61L24/06A61L24/046A61L24/0015A61L24/001A61L2300/204A61L2300/256A61L2300/416A61L2300/602C08L5/08C08L29/04C08L67/04
Inventor 赵一麟周媛媛刘凤武
Owner 太阳雨林(厦门)生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products